Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Adult | US | 2021

Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-ASAs), which are often effective for those patients with mild to moderate disease, but then progresses to more-potent drugs, such as immunosuppressants and/or biologics, as needed. Among the biologics, TNF-alpha inhibitors (Janssen’s Remicade and AbbVie’s Humira) and the cell adhesion molecule (CAM) inhibitor (Takeda’s Entyvio) are the mainstays of treatment. However, therapies such as Pfizer’s Xeljanz / Xeljanz XR, the first approved oral Jak inhibitor, and Janssen’s Stelara are increasing the competition in the later-line settings.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult UC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult UC patients?
  • How have Stelara, Entyvio, and Xeljanz / Xeljanz XR been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of adult UC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of adult UC patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.


The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Markets covered: United States

Key companies: AbbVie, Janssen, Pfizer, Takeda, UCB

Key drugs: Cimzia, Entyvio, Humira, Remicade, Simponi, Stelara, Xeljanz / Xeljanz XR

Login to access report

launch Related Market Assessment Reports